BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avion Pharmaceuticals, LLC, featured on The Balancing Act® on Lifetime® Television Network


11/20/2012 9:21:10 AM

ATLANTA, Nov. 20, 2012 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced its partnership with The Balancing Act®, a daily morning talk show on the Lifetime® Television Network devoted to supporting women. At 7 a.m. EST on Monday, Nov. 26, 2012, The Balancing Act® will re-air a segment on the importance of proper nutrition during pregnancy and will feature information about the innovative new prenatal vitamin, the Prenate Mini. Prenate Mini is the smallest prescription prenatal vitamin with a comprehensive formulation that contains 350 mg of DHA.

The Balancing Act® segment features information shared by a women's healthcare expert about the importance of taking 1 mg of folic acid daily before and during pregnancy to help prevent neural tube defects. Prenate Mini from Avion Pharmaceuticals contains 1 mg of folic acid in the form of Quatrefolic®. The fourth generation folate that is found in the Prenate Vitamin Family, Quatrefolic, is the active form of folate that is beneficial to women including the 50 percent of women who have an impaired ability to break down folic acid.

"Avion is thrilled to support the Balancing Act® and other important women's health programming designed to help women make informed decisions in life related to health & nutrition, fitness, parenting and other important topics," said Mike Sullivan, Vice President, Sales and Marketing, for Avion Pharmaceuticals. "Prenate Mini is the first of many innovative nutritional offerings that Avion will be offering women. Prenate Mini is unique in its size and nutritional value, using the next generation folate (Quatrefolic), DHA and essential vitamins and minerals all in one easy-to-swallow gel cap. We couldn't be more proud to feature this product on Lifetime Television Network."

Avion Pharmaceuticals CEO Mark Pugh added, "Avion is passionate in our commitment to support Women's Health with ongoing partnerships that are targeted to provide information and education in support of healthy pregnancies. In addition, we will continue to focus on the development of unique and innovative product solutions designed for today's moms and babies."

The Nov. 26 Balancing Act® segment featuring Prenate Mini also is available to view online by visiting www.prenate.com. In addition, viewers of the Lifetime Television Network also have several online options for staying informed about upcoming airings of Balancing Act®:

The Balancing Act Viewers Club: http://www.thebalancingact.com/login.php
Facebook like us at: http://www.facebook.com/TheBalancingActFans

About Avion Pharmaceuticals, LLC

Avion Pharmaceuticals, LLC, is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.

SOURCE Avion Pharmaceuticals, LLC



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES